Design for the Patient Experience
ICON is empowering patients, encouraging compliance, and easing the burden of participating in trials through its patient centred services, backed by extensive research on behavioural decision-making and information technology.
Thanks to the web, community groups on social media (such as patient advocacy groups) and real-time access to physiological data from wearables and smartphone apps, patients can be better informed than they ever have been.
Identifying and addressing unmet patient needs is, and always will be, the ultimate goal of pharmaceutical R&D. Therefore, new clinical trial models and the technologies behind them should be harnessed to achieve those goals. In many cases, technology that allows constant monitoring of, and communication with, patients in real time creates the possibility to assess the results of therapies at a level of granularity and over a range of real-world conditions never before imagined – and to intervene in real time if necessary to improve patients’ lives.
Supported by regulatory developments and industry guidance, the culture of clinical research is evolving from one directed by researchers to one driven by the needs of patients and those who care for them. Among the possibilities for making trials more responsive to patient needs are:
These topics are discussed in detail in our industry survey and whitepaper 'Improving Pharma R&D Efficiency' Download your copy today to read more.
Decentralised and hybrid trials are widely discussed in the pharmaceutical industry and are already being deployed on some clinical studies.
ICON conducted a survey through its Global Site Network to get the patient view and find out whether bringing the trial to the patient could make a difference in accessing more patients. We explored perceptions and preferences around what makes it easier for patients to participate in clinical trials and to determine whether industry perception was reality.Read the survey
In our latest whitepaper, we follow a theoretical patient through the entire clinical trial journey – from initial contact for an early study through transition to treatment with an approved product. At each stage, we explore how IoMT can increase clinical development programme efficiency by reducing the burden on patients, caregivers, pharma companies and medical device and diagnostic manufacturers.Read the whitepaper
Many patients with serious diseases cannot wait for an investigational product to move from the lab to the pharmacy shelf. Managed Access Programs are one solution for early access to investigational products. Read our whitepaper to prepare for the clinical and operational complexities.
While pharma has historically focused their medical communications strategies and scientific data dissemination plans to physicians and payers, they have done little to explore the needs of nurses, who also play a central role in patient care. We surveyed 100+ oncology nurses to understand their medical communication needs and preferences and to identify any gaps.
Read our whitepaper for insights on how to design and execute a medical communications program that speaks directly to nurses for greater patient access and engagement across therapeutic areas.
Thanks to the web, community groups on social media (such as patient-advocacy groups) and real-time access to physiological data from wearables and smartphone apps, patients can be better informed than they ever have been.
ICON is working with the International Consortium for Health Outcomes Measurement (ICHOM) to develop The Global Outcomes Benchmarking (GLOBE) program. Rather than focusing on clinical indicators, ICHOM shifts the focus to outcomes that patients care about, including functional improvements and the capacity to live productive lives.
ICON Insights: mHealth Devices Allow for Better Treatments and Clinical Outcomes - Continuous monitoring of patients enables continuous treatment adjustments and alerts clinicians when emergencies arise - resulting in better, more personalised treatment and improved clinical outcomes, with fewer clinic visits and greater independence for patients.
The long journey towards patient centricity - A look at the regulatory efforts implemented in the last 30 years to include the patients’ perspective into drug development.
Patient Centric Monitoring is ICON’s methodology for the design and execution of an adaptive risk based monitoring strategy guided by risk assessment using ICONIK analysis. Risk based monitoring in clinical trials is a monitoring approach where activities, resources and technologies are adapted to the risks in the study. Patient Centric Monitoring further focuses on the probability of errors that matter in decision making for patients.
Today, fewer and fewer patients passively accept physicians’ advice. Patients are increasingly active, informed consumers entering clinics armed with research and opinions about their healthcare options. They desire data on similar patients while calculating the benefits and risks of their choices. To the patient–consumer, "precision medicine" represents the ideal standard of care: the individualised, evidence-based treatment that provides the best opportunity for a positive outcome. Read our three-part series exploring the patient-consumer:
Part One: From Biomarkers to Biosensors
If you would like to receive our Patient Centricity email updates, including the latest on companion diagnostics, drug safety, optimising late phase studies, as well as patient reported outcomes and site and patient recruitment, visit our preference centre.Receive Patient Centricity Email Updates
Registries are economical and flexible, and ideal for collecting data from a wide range of patients and sites, generating the real world evidence regulators and payers require to demonstrate effectiveness and safety, and to support label and coverage extensions. But this flexibility also creates risk. To generate useable, uniform data, registries must be carefully designed and administered. Consider these seven factors as you design and launch a successful registry.